- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Amgen buys Dark Blue Therapeutics in $840m oncology deal | ||
| 13:46 | Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus | ||
| 11:46 | Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis | ||
| 10:46 | Zai Lab's Augtyro receives NMPA approval for solid tumours in China | ||
| Di | CDC shrinks childhood vaccine recommendation list to mirror "peer nations" | ||
| Di | Takeda and Protagonist seek FDA approval for rusfertide to treat PV | ||
| Di | Aktis Oncology kicks 2026 IPO cycle off with $210m target | ||
| Di | Arrowhead receives Health Canada authorisation for Redemplo to treat FCS | ||
| Mo | Sanofi and Earendil Labs forge $2.56bn autoimmune deal | ||
| Mo | Insilico and Servier announce $888m oncology research agreement | ||
| Mo | Biogen's Tysabri to be used on England's NHS for highly active MS | ||
| Mo | Samsung Bioepis initiates Byooviz commercialisation in Europe | ||
| Fr | Valneva takes back charge of chikungunya vaccine supply in Asia | ||
| Fr | Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD | ||
| 31.12.25 | FDA approves Vanda Pharmaceuticals' motion sickness drug Nereus | ||
| 31.12.25 | Emmaus, NIT sign Endari distribution agreement | ||
| 30.12.25 | Genmab shelves Phase III lung cancer candidate | ||
| 30.12.25 | Johnson & Johnson acquires Halda Therapeutics for $3.05bn | ||
| 29.12.25 | Sanofi buys hep B vaccine maker for $2.2bn | ||
| 29.12.25 | Revamping best-selling drugs to combat patent cliff has limits | ||
| 29.12.25 | Innovent receives NMPA approval for Tabosun colon cancer treatment | ||
| 26.12.25 | Gilead Sciences to acquire Repare's RP-3467 | ||
| 24.12.25 | Zydus and Bioeq partner for commercialisation of Nufymco in US | ||
| 23.12.25 | Ipsen outlays $1bn for China-based Simcere's preclinical ADC | ||
| 23.12.25 | Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .